SRB Environment Evaluation and Analysis. Volume 3: ASRB Plume Induced Environments

Contract NAS8-37891 was expanded in late 1989 to initiate analysis of Shuttle plume induced environments as a result of the substitution of the Advanced Solid Rocket Booster (ASRB) for the Redesigned Solid Rocket Booster (RSRB). To support this analysis, REMTECH became involved in subscale and full-scale solid rocket motor test programs which further expanded the scope of work. Later contract modifications included additional tasks to produce initial design cycle environments and to specify development flight instrumentation. Volume 3 of the final report describes these analyses and contains a summary of reports resulting from various studies

Auxetic cardiac patches with tunable mechanical and conductive properties toward treating myocardial infarction

An auxetic conductive cardiac patch (AuxCP) for the treatment of myocardial infarction (MI) is introduced. The auxetic design gives the patch a negative Poisson's ratio, providing it with the ability to conform to the demanding mechanics of the heart. The conductivity allows the patch to interface with electroresponsive tissues such as the heart. Excimer laser microablation is used to micropattern a re-entrant honeycomb (bow-tie) design into a chitosan-polyaniline composite. It is shown that the bow-tie design can produce patches with a wide range in mechanical strength and anisotropy, which can be tuned to match native heart tissue. Further, the auxetic patches are conductive and cytocompatible with murine neonatal cardiomyocytes in vitro. Ex vivo studies demonstrate that the auxetic patches have no detrimental effect on the electrophysiology of both healthy and MI rat hearts and conform better to native heart movements than unpatterned patches of the same material. Finally, the AuxCP applied in a rat MI model results in no detrimental effect on cardiac function and negligible fibrotic response after two weeks in vivo. This approach represents a versatile and robust platform for cardiac biomaterial design and could therefore lead to a promising treatment for MI

Role of mass drug administration in elimination of Plasmodium falciparum malaria: a consensus modelling study

Background Mass drug administration for elimination of Plasmodium falciparum malaria is recommended by WHO in some settings. We used consensus modelling to understand how to optimise the effects of mass drug administration in areas with low malaria transmission. Methods We collaborated with researchers doing field trials to establish a standard intervention scenario and standard transmission setting, and we input these parameters into four previously published models. We then varied the number of rounds of mass drug administration, coverage, duration, timing, importation of infection, and pre-administration transmission levels. The outcome of interest was the percentage reduction in annual mean prevalence of P falciparum parasite rate as measured by PCR in the third year after the final round of mass drug administration. Findings The models predicted differing magnitude of the effects of mass drug administration, but consensus answers were reached for several factors. Mass drug administration was predicted to reduce transmission over a longer timescale than accounted for by the prophylactic effect alone. Percentage reduction in transmission was predicted to be higher and last longer at lower baseline transmission levels. Reduction in transmission resulting from mass drug administration was predicted to be temporary, and in the absence of scale-up of other interventions, such as vector control, transmission would return to pre-administration levels. The proportion of the population treated in a year was a key determinant of simulated effectiveness, irrespective of whether people are treated through high coverage in a single round or new individuals are reached by implementation of several rounds. Mass drug administration was predicted to be more effective if continued over 2 years rather than 1 year, and if done at the time of year when transmission is lowest. Interpretation Mass drug administration has the potential to reduce transmission for a limited time, but is not an effective replacement for existing vector control. Unless elimination is achieved, mass drug administration has to be repeated regularly for sustained effect

Automatically Improving Constraint Models in Savile Row through Associative-Commutative Common Subexpression Elimination

When solving a problem using constraint programming, constraint modelling is widely acknowledged as an important and difficult task. Even a constraint modelling expert may explore many models and spend considerable time modelling a single problem. Therefore any automated assistance in the area of constraint modelling is valuable. Common sub-expression elimination (CSE) is a type of constraint reformulation that has proved to be useful on a range of problems. In this paper we demonstrate the value of an extension of CSE called Associative-Commutative CSE (AC-CSE). This technique exploits the properties of associativity and commutativity of binary operators, for example in sum constraints. We present a new algorithm, X-CSE, that is able to choose from a larger palette of common subexpressions than previous approaches. We demonstrate substantial gains in performance using X-CSE. For example on BIBD we observed speed increases of more than 20 times compared to a standard model and that using X-CSE outperforms a sophisticated model from the literature. For Killer Sudoku we found that X-CSE can render some apparently difficult instances almost trivial to solve, and we observe speed increases up to 350 times. For BIBD and Killer Sudoku the common subexpressions are not present in the initial model: an important part of our methodology is reformulations at the preprocessing stage, to create the common subexpressions for X-CSE to exploit. In summary we show that X-CSE, combined with preprocessing and other reformulations, is a powerful technique for automated modelling of problems containing associative and commutative constraints

Sigma-term physics in the perturbative chiral quark model

We apply the perturbative chiral quark model (PCQM) at one loop to analyse meson-baryon sigma-terms. Analytic expressions for these quantities are obtained in terms of fundamental parameters of low-energy pion-nucleon physics (weak pion decay constant, axial nucleon coupling, strong pion-nucleon form factor) and of only one model parameter (radius of the nucleonic three-quark core). Our result for the piN sigma term of about 45 MeV is in good agreement with the value deduced by Gasser, Leutwyler and Sainio using dispersion-relation techniques and exploiting the chiral symmetry constraints.Comment: 19 pages, LaTeX-file, 2 Figure

Baryon masses in a chiral expansion with meson-baryon form factors

The chiral expansion of the one-loop corrections to baryon masses is examined in a generic meson-cloud model with meson-baryon form factors. For pion loops, the expansion is rapidly convergent and at fourth order in $m_\pi$ accurately reproduces the full integral. In contrast, the expansion is found to converge very slowly for kaon loops, raising questions about the usefulness of chiral expansions for kaon-baryon physics. Despite the importance of high-order terms, relations like that of Gell-Mann and Okubo are well satisfied by the baryon masses calculated with the full integral. The pion cloud cloud makes a significant contribution to the $\pi N$ sigma commutator, while kaon cloud gives a very small strangeness content in the nucleon.Comment: 20 pages (RevTeX), 2 figures (attached

White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry).

Elevated white blood cell (WBC) count is associated with increased major adverse cardiovascular events (MACE) in the setting of acute coronary syndrome. The aim of this study was to evaluate whether similar associations persist in an all-comers population of patients undergoing percutaneous coronary intervention in the contemporary era. In the multicenter, prospective, observational PARIS study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry), 4222 patients who underwent percutaneous coronary intervention in the United States and Europe between July 1, 2009, and December 2, 2010, were evaluated. The associations between baseline WBC and MACE (composite of cardiac death, stent thrombosis, spontaneous myocardial infarction, or target lesion revascularization) at 24-month follow-up were analyzed using multivariable Cox regression. Patients with higher WBC were more often younger, smokers, and with less comorbid risk factors compared with those with lower WBC. After adjustment for baseline and procedural characteristics, WBC remained independently associated with MACE (hazard ratio [HR] per 10(3) cells/μL increase, 1.05 [95% confidence intervals (CI), 1.02-1.09]; P=0.001), cardiac death (HR, 1.10 [95% CI, 1.05-1.17]; P<0.001), and clinically indicated target revascularization (HR, 1.04 [95% CI, 1.00-1.09]; P=0.03) but not stent thrombosis (HR, 1.07 [95% CI, 0.99-1.16]; P=0.10) or spontaneous myocardial infarction (HR, 1.03 [95% CI, 0.97-1.09]; P=0.29). The association between WBC and MACE was consistent in acute coronary syndrome and non-acute coronary syndrome presentations (interaction P=0.15). Increased WBC is an independent predictor of MACE after percutaneous coronary intervention in a contemporary all-comers cohort. Further studies to delineate the underlying pathophysiologic role of elevated WBC across a spectrum of coronary artery disease presentations are warranted. URL: http://www.clinicaltrials.gov. Unique identifier: NCT00998127

Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry).

Temporary interruption of dual antiplatelet therapy (DAPT) is not infrequently required in patients undergoing percutaneous coronary intervention (PCI). We sought to describe the procedures and outcomes associated with DAPT interruption in patients treated with DAPT following successful PCI from the Patterns of non-adherence to anti-platelet regimens in stented patients registry (n = 5018). DAPT interruption was prespecified as physician recommended cessation for <14 days. Of the study cohort, 490 patients (9.8%) experienced 594 DAPT interruptions over 2 years following PCI. Only 1 antiplatelet agent was interrupted in 57.2% cases and interruption was frequently recommended by noncardiologists (51.3%). Where type of surgery was reported, majority of DAPT interruptions occurred for minor surgery (68.4% vs 31.6%) and a similar cessation pattern of single versus dual antiplatelet cessation was observed regardless of minor or major surgery. Subsequent to DAPT interruption, 12 patients (2.4%) experienced 1 thrombotic event each, of which 5 (1.0%) occurred during the interruption period. All events occurred in patients who either stopped both agents (8 of 12) or clopidogrel-only (4 of 12), with no events occurring due to aspirin cessation alone. In conclusion, in the Patterns of Non-adherence to Anti-platelet Regiments in Stented Patients registry, 1 in 10 patients were recommended DAPT interruption for surgery within 2 years of PCI. Interruption was more common for a single agent rather than both antiplatelet agents regardless of severity of surgery, and was frequently recommended by noncardiologists. Only 1% of patients with DAPT interruption experienced a subsequent thrombotic event during the interruption period, which mainly occurred in patients stopping both antiplatelet agents

Phospholipase D Family Member 4, a Transmembrane Glycoprotein with No Phospholipase D Activity, Expression in Spleen and Early Postnatal Microglia

BACKGROUND: Phospholipase D (PLD) catalyzes conversion of phosphatidylcholine into choline and phosphatidic acid, leading to a variety of intracellular signal transduction events. Two classical PLDs, PLD1 and PLD2, contain phosphatidylinositide-binding PX and PH domains and two conserved His-x-Lys-(x)(4)-Asp (HKD) motifs, which are critical for PLD activity. PLD4 officially belongs to the PLD family, because it possesses two HKD motifs. However, it lacks PX and PH domains and has a putative transmembrane domain instead. Nevertheless, little is known regarding expression, structure, and function of PLD4. METHODOLOGY/PRINCIPAL FINDINGS: PLD4 was analyzed in terms of expression, structure, and function. Expression was analyzed in developing mouse brains and non-neuronal tissues using microarray, in situ hybridization, immunohistochemistry, and immunocytochemistry. Structure was evaluated using bioinformatics analysis of protein domains, biochemical analyses of transmembrane property, and enzymatic deglycosylation. PLD activity was examined by choline release and transphosphatidylation assays. Results demonstrated low to modest, but characteristic, PLD4 mRNA expression in a subset of cells preferentially localized around white matter regions, including the corpus callosum and cerebellar white matter, during the first postnatal week. These PLD4 mRNA-expressing cells were identified as Iba1-positive microglia. In non-neuronal tissues, PLD4 mRNA expression was widespread, but predominantly distributed in the spleen. Intense PLD4 expression was detected around the marginal zone of the splenic red pulp, and splenic PLD4 protein recovered from subcellular membrane fractions was highly N-glycosylated. PLD4 was heterologously expressed in cell lines and localized in the endoplasmic reticulum and Golgi apparatus. Moreover, heterologously expressed PLD4 proteins did not exhibit PLD enzymatic activity. CONCLUSIONS/SIGNIFICANCE: Results showed that PLD4 is a non-PLD, HKD motif-carrying, transmembrane glycoprotein localized in the endoplasmic reticulum and Golgi apparatus. The spatiotemporally restricted expression patterns suggested that PLD4 might play a role in common function(s) among microglia during early postnatal brain development and splenic marginal zone cells

Exploiting short supports for improved encoding of arbitrary constraints into SAT

Encoding to SAT and applying a highly efficient modern SAT solver is an increasingly popular method of solving finite-domain constraint problems. In this paper we study encodings of arbitrary constraints where unit propagation on the encoding provides strong reasoning. Specifically, unit propagation on the encoding simulates generalised arc consistency on the original constraint. To create compact and efficient encodings we use the concept of short support. Short support has been successfully applied to create efficient propagation algorithms for arbitrary constraints. A short support of a constraint is similar to a satisfying tuple however a short support is not required to assign every variable in scope. Some variables are left free to take any value. In some cases a short support representation is smaller than the table of satisfying tuples by an exponential factor. We present two encodings based on short supports and evaluate them on a set of benchmark problems, demonstrating a substantial improvement over the state of the art